|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
|
27637890 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, peptide inhibition of BCL6 in human CML cells compromises colony formation and leukemia initiation in transplant recipients and selectively eradicates CD34(+) CD38(-) LICs in patient-derived CML samples.
|
21911423 |
2011 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To clarify the clinical features of t(10;11)-leukemias, we investigated 6 samples from acute leukemia patients with t(10;11) and MLL rearrangement and detected MLL-AF10 chimeric transcripts in 5 samples and MLL-ABI1 in one.
|
11477655 |
2001 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, CD34+/CD38- leukemia precursors, in contrast with CD38+ precursors, failed, under appropriate conditions, to differentiate into dendritic cells, a central step for antigen recognition.
|
10969785 |
2000 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.
|
21330473 |
2011 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(10;11) translocation results in a CALM-AF10 fusion gene in a subset of leukemia patients.
|
20007546 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that clonal karyotypic abnormalities are frequently found in the stem cell-like (CD34+/CD38-) and more mature (CD34+/CD38+) populations of patients with AML, irrespective of the phenotype of the bulk population of leukemic blasts and of the primary or secondary character of the leukemia.
|
7579382 |
1995 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of six small molecule pharmacological agents, which interfere with endocytic and other processes, on SA-mediated augmentation of saporin and saporin-based immunotoxins (ITs) directed against CD7, CD19, CD22 and CD38 on human lymphoma and leukaemia cell lines.
|
30791598 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One-third of the leukemia cells expressed a mature suppressor/cytotoxic T cell phenotype (T3+ T4- T6- T8+ T10-), two-thirds demonstrated additional helper/inducer T cell-associated antigens (T3+ T4+ T6- T8+ T10-), and a small fraction reacted with a natural killer (NK) cell-specific monoclonal antibody (Leu 11+).
|
2942200 |
1986 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we characterize two additional t(X;14) bearing leukemias allowing this analysis.
|
9315101 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relapse of acute myeloid leukemia (AML) is thought to reflect the failure of current therapies to adequately target leukemia stem cells (LSCs), the rare, resistant cells presumed responsible for maintenance of the leukemia and typically enriched in the CD34(+)CD38(-) cell population.
|
22262762 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously showed that CD34⁺/CD38⁻ acute myelogenous leukemia (AML) cells, which contain leukemia stem cells, expressed a greater amount of the phosphorylated forms of JAK2 and STAT5 (p-JAK2 and p-STAT5) than their CD34⁺/CD38⁺ counterparts.
|
23564444 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38 is both a positive and negative prognostic indicator in leukaemia.
|
29234114 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Development of T-cell leukaemia in an ataxia telangiectasia patient following clonal selection in t(X;14)-containing lymphocytes.
|
1518308 |
1992 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
No statistically significant differences were observed at diagnosis between patients with the CC genotype and homozygous or heterozygous T allele carriers with respect to age at disease onset, sex distribution, proportion of patients with CD38+ leukaemia or patients in Binet stage A, blood cell counts, degree of bone marrow infiltration or serum levels of lactate dehydrogenase, thymidine kinase or beta2-microglobulin.
|
14692527 |
2003 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta.
|
21393419 |
2011 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(10;11)(p13;q14-21) is a non-random translocation described in acute lymphoblastic and myeloid leukaemias.
|
11417476 |
2001 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that the leukemia with inv(3)(q21q26) represents a new cytogenetic-clinicopathologic subtype, characterized by 1) abnormal megakaryopoiesis and multiple hematopoietic lineage involvement; 2) an antecedent MDS; 3) poor response to conventional chemotherapy; and 4) expression of CD7, CD34, CD38, HLA-DR, CD13, and CD33 antigens.
|
9209472 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38 is a powerful disease marker for human leukemias and myelomas, is directly involved in the pathogenesis and outcome of human immunodeficiency virus infection and chronic lymphocytic leukemia, and controls insulin release and the development of diabetes.
|
18626062 |
2008 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(10;11)(p13;q14-21) is a non-random translocation that occurs primarily in T cell acute lymphoblastic leukemias (T-ALL), but has also been observed in leukemias and lymphomas of diverse lineages.
|
9737689 |
1998 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
People with ataxia telangiectasia (AT) are at a higher than normal risk of T cell leukaemia and often have either non-malignant or malignant T cells with chromosomal abnormalities, typically t(14;14), inversion 14 or more rarely t(X;14).
|
8036021 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In clinics, CD38 was adopted as a cell activation marker and in the diagnostic/staging of leukemias.
|
31783629 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have also shown that CD34(+) /CD38(-) AML cells, one of compartments enriched for leukemia stem cells in most leukemia subgroups, were relatively resistant to cytarabine-mediated growth inhibition when compared to their CD34(+) /CD38(+) counterparts.
|
23686525 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xenograft transplantation studies have demonstrated a rare population of leukemia-initiating cells called leukemic stem cells (LSCs) capable of propagating leukemia that are enriched in the CD34+/CD38- fraction.
|
27465508 |
2016 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca<sup>2+</sup> activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation.
|
30733502 |
2019 |